Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07103655 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction

Study acronym: BRAVE-HCM
StatusEnrolling by Invitation
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Jul 1, 2026 → Nov 1, 2026
See other at-risk trials from Second Affiliated Hospital, Zhejiang University, School of Medicine

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrolling by invitation only Show 5 more changesShow less
    • Primary completion pushed from Jul 1, 2026 to Nov 1, 2026
    • Start date changed from estimate of Jan 1, 2026 to Mar 1, 2026
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 4 of 11 entries
    • Site contact updated
  2. Changed Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University to Second Affiliated Hospital, Zhejiang University, School of Medicine
  3. Secondary endpoints: 10 to 11v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a prospective interventional cohort study aimed at evaluating the therapeutic efficacy and clinical utility of Mavacamten-a targeted myosin inhibitor specifically developed for obstructive hypertrophic cardiomyopathy (HCM)-in patients with HCM characterized by mid-to-apical left ventricular obstruction.
Trial Details
NCT Number NCT07103655
Lead Sponsor Second Affiliated Hospital, Zhejiang University, School of Medicine
Conditions
(from sponsor)		 Hypertrophic Cardiomyopathy (HCM)
Related terms Cardiomyopathy, Hypertrophic
Enrollment 132 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov